Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (50713)	1/31/2019 9:21:21 PM
From: Miljenko Zuanic	Respond to of 52153

NASH drug is for pro-/pre-diabetic, obese, triglyceride,....or some other co-morbidity. So, bi-weekly or monthly (antibody),...or maybe even weekly with strong efficacy (or combination) may compete tomorrow with oral. Majority candidates are liver-targeted (with some additional tissue-site of action),...so large proteins may not be best choice, if not preferentially absorbed by liver. I do prefer oral candidate for this indication, as long as oral does not harm liver itself.